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B7-H4 is a member of the B7 family of co-regulatory
receptors. It is believed to negatively regulate T cell func-
tion and has been associated with poor prognosis in renal
cell and ovarian cancers. We performed an unbiased ana-
lysis of TCGA gene expression data and identified triple
negative breast cancer (TNBC) as having the greatest
absolute B7-H4 mRNA level of all tumors analyzed.
Recent clinical studies with anti-PD-1 or PD-L1 therapies
have reported promising activity in TNBC leading us to
investigate check point molecule expression (PD-1, PD-L1
and B7-H4) as well as expression of immune cell infiltra-
tion (CD8, Fox P3) in archival samples from a cohort of
96 TNBC patients collected at Yale University.
We developed a specific and sensitive immunohisto-
chemistry (IHC) assay for evaluating B7-H4 protein and
used an immunofluorescence-based multiplex IHC for
assessing combinations of checkpoint molecules in the
TNBC samples. The majority of tumors had detectable
B7-H4 expression, whereas PD-L1 expression was
restricted to a subset of TNBC patients (~20% having >5%
PD-L1 positive cells). Multiplex IHC and flow cytometry
studies showed that the majority of B7-H4 expression was
restricted to the tumor epithelial cells, while the CD45+
immune cells were negative for B7-H4 expression. Inter-
estingly, a majority of the B7-H4 high tumors were nega-
tive or showed scant PD-L1 staining. In addition, cells that
are B7-H4 positive are negative for PD-L1 staining,
suggesting that B7-H4 and PD-L1 checkpoint proteins
may act in a mutually exclusive manner. B7-H4 expression
was not associated with overall survival, disease stage,
nodal status, or other clinical characteristics. In contrast,
PD-L1, PD-1, and CD8 expression all conferred a signifi-
cant survival advantage in TNBC, thus highlighting the
importance of the immune response in this disease.
Upon further investigation, and contrary to published lit-
erature, we were unable to show a definitive immunosup-
pressive role of B7-H4. However B7-H4 over-expression in
CT-26 syngeneic in vivo model accelerated tumor growth.
The unique expression pattern of B7-H4 on TNBC sug-
gests an opportunity for targeted approaches with possible
immunomodulatory activity. Additional work is needed to
further clarify the immunological mechanisms of B7-H4,
but we believe its unique expression pattern makes B7-H4
an attractive target for the treatment of TNBC.
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